Liraglutide Injections and Saxenda Therapy in Fishers, IN

Liraglutide injections with Saxenda are an FDA-approved treatment for chronic weight reduction and long-term weight management in appropriate adults and adolescents.

Saxenda contains liraglutide, a glucagon-like peptide-1 receptor agonist, commonly called a GLP-1 receptor agonist.

Liraglutide can help:

• Reduce hunger
• Increase fullness
• Reduce calorie intake
• Improve control over eating
• Support sustained weight reduction when combined with nutrition and physical activity

Saxenda is administered once daily rather than once weekly.

Current FDA-approved use includes:

• Adults with obesity
• Adults with overweight and at least one weight-related medical condition
• Adolescents age 12 years and older with obesity who weigh more than 60 kg, or approximately 132 pounds

FDA also approved the first generic liraglutide referencing Saxenda in August 2025.

There is another important 2026 development: Novo Nordisk has announced that branded Saxenda will be discontinued, with final shipments to wholesalers expected in late January 2027. The manufacturer states that this is a strategic portfolio decision and is not related to a safety or quality concern.

Patients currently using Saxenda should therefore discuss future access, FDA-approved generic liraglutide and other Saxenda alternatives before supplies become limited.

A physician-guided medical weight-loss program can help determine whether liraglutide remains appropriate, monitor side effects and build a long-term weight-maintenance strategy.

To discuss liraglutide and Saxenda therapy in Fishers, IN, call (765) 259-0545 or contact Charles Turner MD online.

What Is Saxenda?

Saxenda is the FDA-approved brand of liraglutide used for chronic weight management.

Liraglutide is a long-acting analogue of naturally occurring glucagon-like peptide-1.

GLP-1 is released from the gastrointestinal tract after eating and helps regulate:

• Appetite
• Satiety
• Glucose-dependent insulin secretion
• Glucagon secretion
• Gastric emptying
• Food intake

Liraglutide was modified to remain active much longer than naturally occurring GLP-1.

That extended activity allows once-daily injection.

Is Liraglutide a Peptide?

Yes.

Liraglutide is a peptide-based GLP-1 receptor agonist.

It is structurally related to human GLP-1 but has been modified to prolong its activity.

Those modifications allow liraglutide to remain in circulation long enough for daily administration.

How Does Saxenda Help With Weight Loss?

Saxenda primarily works by helping patients consume fewer calories.

GLP-1 receptor activation can influence brain pathways involved in:

• Hunger
• Satiety
• Meal size
• Food reward
• Energy intake

Patients may notice:

• Less hunger between meals
• Earlier fullness while eating
• Longer-lasting satiety
• Smaller portion sizes
• Improved control over food intake

Saxenda does not directly dissolve body fat.

Weight loss occurs primarily because sustained appetite regulation helps reduce calorie intake over time.

Who Is Saxenda FDA-Approved For?

Current labeling indicates Saxenda, together with reduced-calorie nutrition and increased physical activity, for long-term weight management in:

• Adults with obesity
• Adults with overweight and at least one weight-related comorbid condition
• Pediatric patients age 12 years and older who weigh more than 60 kg and have obesity

Weight-related conditions can include:

• High blood pressure
• Abnormal cholesterol
• Type 2 diabetes
• Obstructive sleep apnea
• Other obesity-related medical conditions

How Is Saxenda Dosed?

Saxenda uses a gradual five-week dose-escalation schedule.

The usual adult schedule is:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 and thereafter: 3.0 mg once daily

For adults, 3.0 mg once daily is the recommended maintenance dose.

The lower doses are used during titration rather than as standard adult maintenance doses.

Why Is the Saxenda Dose Increased Slowly?

Gradual escalation improves gastrointestinal tolerability.

Starting immediately at the full 3 mg dose would increase the likelihood of:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Difficulty maintaining hydration

If an adult cannot tolerate a dose increase, current prescribing guidance allows the clinician to consider delaying escalation for approximately one additional week.

If the adult patient cannot tolerate the 3 mg dose, treatment should be discontinued rather than maintained indefinitely at a lower dose without appropriate medical review.

What Is the Saxenda Dose for Adolescents?

Adolescents also begin at 0.6 mg once daily and increase gradually.

The target dose is 3.0 mg daily.

Current patient information notes that a clinician may reduce the adolescent dose to 2.4 mg daily if 3.0 mg is not tolerated.

Pediatric treatment should be managed by a clinician familiar with adolescent obesity.

When Should Saxenda Be Stopped for Lack of Weight Loss?

The adult Saxenda treatment program includes an important early-response checkpoint.

At 16 weeks after starting treatment, the adult patient's weight response should be evaluated.

If the patient has not lost at least:

4% of baseline body weight

current prescribing guidance recommends discontinuing Saxenda because continued clinically meaningful weight loss is unlikely.

Why Does the 16-Week Saxenda Checkpoint Matter?

A pooled analysis of the SCALE clinical program found that losing at least 4% of baseline weight by week 16 was useful for identifying patients more likely to achieve clinically meaningful one-year weight loss.

Among adults without type 2 diabetes:

• 77.3% were early responders
• Early responders lost an average of 10.8% at week 56
• Early nonresponders lost an average of 3.0%

This stopping rule helps avoid continuing medication that is unlikely to provide enough benefit for a particular patient.

How Is Saxenda Injected?

Saxenda is injected under the skin once daily.

Approved injection areas include:

• Abdomen
• Thigh
• Upper arm

The medication can be administered at any time of day and does not need to be coordinated with meals.

Injection sites should be rotated rather than repeatedly using the exact same location.

How Does the Saxenda Pen Work?

Saxenda is supplied in a prefilled multi-dose pen.

The patient attaches a new disposable needle for each injection and selects the prescribed dose.

Patients should receive instruction on:

• Attaching and removing the needle
• Checking medication flow when appropriate
• Selecting the correct dose
• Rotating injection sites
• Storing the pen correctly
• Using an appropriate sharps container

The Saxenda pen should never be shared with another person, even if the needle is changed.

What If a Saxenda Dose Is Missed?

If a daily dose is missed, the patient should generally take the next scheduled daily dose as usual.

Do not:

• Take an extra dose
• Double the next dose
• Increase the next dose to compensate

If Saxenda has not been taken for three days or more, the patient should contact the prescribing clinician to discuss how to restart treatment.

How Much Weight Can Patients Lose With Saxenda?

The pivotal SCALE Obesity and Prediabetes trial enrolled 3,731 adults without type 2 diabetes.

Participants had obesity or overweight with dyslipidemia or hypertension and received either:

• Liraglutide 3.0 mg once daily
• Placebo

Both groups also received lifestyle counseling.

At 56 weeks, average weight loss was:

• 8.4 kg with liraglutide
• 2.8 kg with placebo

How Many Patients Lost at Least 5% With Saxenda?

In the same pivotal trial:

• 63.2% of liraglutide-treated participants lost at least 5% of starting body weight
• 27.1% of placebo-treated participants lost at least 5%

More substantial weight loss also occurred more often with liraglutide.

How Many Patients Lost More Than 10%?

In SCALE Obesity and Prediabetes:

• 33.1% of liraglutide-treated participants lost more than 10% of starting body weight
• 10.6% of placebo-treated participants lost more than 10%

Individual response can be greater or smaller than these averages.

How Much Weight Can Patients Lose Over Three Years?

The SCALE Obesity and Prediabetes program followed a prediabetes subgroup for approximately three years.

At week 160, average weight change was:

• 6.1% reduction with liraglutide
• 1.9% reduction with placebo

The trial also studied progression from prediabetes to type 2 diabetes.

Saxenda and Prediabetes

Among adults with obesity or overweight and prediabetes, type 2 diabetes was diagnosed during treatment in approximately:

• 2% of liraglutide-treated participants
• 6% of placebo-treated participants

Time to diabetes diagnosis was significantly longer with liraglutide.

This is clinically important research, but Saxenda should not be described as an FDA-approved diabetes-prevention medication.

Patients with insulin resistance or prediabetes should receive comprehensive metabolic monitoring.

Saxenda in Adults With Type 2 Diabetes

The SCALE Diabetes trial studied adults with overweight or obesity and type 2 diabetes.

At 56 weeks, average weight reduction was:

• 6.0% with liraglutide 3.0 mg
• 4.7% with liraglutide 1.8 mg
• 2.0% with placebo

At least 5% weight loss occurred in:

• 54.3% receiving liraglutide 3.0 mg
• 21.4% receiving placebo

More than 10% weight loss occurred in:

• 25.2% receiving liraglutide 3.0 mg
• 6.7% receiving placebo

Patients with type 2 diabetes need additional glucose monitoring, especially when insulin or sulfonylurea medications are used.

Saxenda and Weight-Loss Maintenance

The SCALE Maintenance trial evaluated adults who first lost at least 5% of their body weight using a low-calorie diet.

After randomization, participants received liraglutide 3.0 mg or placebo.

During the following 56 weeks:

• Liraglutide-treated participants lost an additional average 6.2%
• Placebo-treated participants lost an additional average 0.2%

Approximately 81.4% of liraglutide-treated participants maintained the initial diet-induced weight loss compared with 48.9% receiving placebo.

This supports Saxenda as a chronic weight-management treatment rather than a short-term crash-diet medication.

Saxenda and Intensive Behavioral Therapy

Medication can work better when integrated with structured behavior change.

In the SCALE IBT randomized trial:

• Liraglutide plus intensive behavioral therapy produced 7.5% average weight loss
• Placebo plus intensive behavioral therapy produced 4.0% average weight loss

At least 5% weight loss occurred significantly more often with the liraglutide combination.

Can More Intensive Lifestyle Treatment Increase Weight Loss?

Another randomized trial evaluated intensive behavioral therapy alone or in combination with liraglutide.

At one year, average weight loss was:

• 6.1% with intensive behavioral therapy alone
• 11.5% with intensive behavioral therapy plus liraglutide
• 11.8% with liraglutide, intensive behavioral therapy and an initial portion-controlled diet

The findings demonstrate that medication and behavioral treatment can complement one another.

GLP-1 weight-loss coaching can help patients translate reduced appetite into sustainable nutrition and activity habits.

Saxenda and Obstructive Sleep Apnea

Obesity is an important risk factor for obstructive sleep apnea .

The SCALE Sleep Apnea trial studied adults with obesity and moderate-to-severe OSA who were unwilling or unable to use continuous positive airway pressure therapy.

After 32 weeks:

• AHI decreased by an average of 12.2 events per hour with liraglutide
• AHI decreased by 6.1 events per hour with placebo
• Average weight loss was 5.7% with liraglutide
• Average weight loss was 1.6% with placebo

The degree of OSA improvement was associated with the degree of weight loss.

Saxenda is not FDA-approved specifically to treat obstructive sleep apnea.

Zepbound has a specific FDA-approved OSA indication for adults with obesity.

Saxenda in Adolescents With Obesity

A randomized trial enrolled 251 adolescents age 12 to younger than 18 years with obesity and inadequate response to lifestyle treatment alone.

Participants received liraglutide or placebo in addition to lifestyle therapy.

At 56 weeks, liraglutide produced a significantly greater improvement in BMI standard-deviation score.

A reduction in BMI of at least 5% occurred in approximately:

• 43.3% of liraglutide-treated adolescents
• 18.7% receiving placebo

A reduction in BMI of at least 10% occurred in approximately:

• 26.1% receiving liraglutide
• 8.1% receiving placebo

These data contributed to the adolescent obesity indication.

Is Saxenda Approved for Children Younger Than 12?

No.

Although clinical research has studied liraglutide in younger children with obesity, the current Saxenda indication begins at age 12.

Research findings in younger children should not be converted into routine treatment recommendations outside appropriate pediatric specialist care.

How Does Saxenda Compare With Wegovy?

Saxenda and Wegovy are both GLP-1 receptor agonists.

• Saxenda: liraglutide, injected once daily
• Wegovy: semaglutide, available in once-weekly injectable and adult oral formulations

A direct randomized trial called STEP 8 compared liraglutide 3.0 mg daily with semaglutide 2.4 mg weekly.

At 68 weeks, average weight reduction was:

• 6.4% with liraglutide
• 15.8% with semaglutide

This demonstrates greater average weight loss with the studied semaglutide regimen.

Individual tolerability, access and treatment goals still matter.

Patients can review semaglutide injections and Wegovy therapy or Wegovy alternatives .

How Does Saxenda Compare With Zepbound?

Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors.

Saxenda contains liraglutide and primarily activates GLP-1 receptors.

Major Zepbound obesity trials have reported larger average weight reductions than the pivotal Saxenda program, although separate trials should not be treated as direct head-to-head evidence.

Zepbound is administered once weekly rather than once daily.

Patients can review tirzepatide injections and Zepbound therapy .

How Does Saxenda Compare With Ozempic?

Saxenda and Ozempic are different medications with different primary indications.

• Saxenda: liraglutide for chronic weight management
• Ozempic: semaglutide primarily for type 2 diabetes with selected cardiovascular and kidney indications

Patients can review semaglutide injections and Ozempic therapy .

How Does Saxenda Compare With Mounjaro?

Mounjaro contains tirzepatide and is primarily the diabetes brand.

For a patient seeking chronic obesity treatment, Zepbound is the more direct tirzepatide comparison.

Patients interested in diabetes-focused tirzepatide can review tirzepatide injections and Mounjaro therapy .

Saxenda and Victoza Contain the Same Active Ingredient

Both Saxenda and Victoza contain liraglutide.

They are different branded products with different FDA-approved indications and dose ranges.

• Saxenda: chronic weight management
• Victoza: type 2 diabetes and selected cardiovascular indications

Saxenda and Victoza should not be used together.

FDA-Approved Generic Liraglutide for Weight Management

FDA approved the first generic liraglutide injection referencing Saxenda on August 27, 2025.

This is important because an FDA-approved generic is fundamentally different from a compounded liraglutide product.

The approved generic completed the federal abbreviated-new-drug-application process.

Its approved use corresponds to the Saxenda weight-management indication.

Generic Liraglutide vs. Saxenda

Comparison	Saxenda	FDA-Approved Generic Liraglutide
Active ingredient	Liraglutide	Liraglutide
FDA-approved	Yes	Yes
Weight-management indication	Yes	Yes, based on the reference product
Generic-drug approval pathway	Reference listed drug	FDA-approved ANDA
Compounded medication	No	No

Saxenda Is Being Discontinued by the Manufacturer

Novo Nordisk has announced that it will discontinue branded Saxenda.

The manufacturer states that:

• Final shipments to wholesalers are expected in late January 2027
• The decision reflects changes in the obesity-treatment market and declining Saxenda use
• The decision is not related to a safety concern
• The decision is not related to a quality concern

Because this change affects future access, patients using Saxenda should begin planning before the final shipments occur.

What Should Current Saxenda Patients Do About the 2027 Discontinuation?

Do not stop treatment abruptly simply because the brand is scheduled for discontinuation.

A clinician can review options such as:

• FDA-approved generic liraglutide referencing Saxenda
• Wegovy
• Zepbound
• Another FDA-approved weight-management medication
• A structured maintenance plan

The best transition depends on:

• Current weight response
• Side effects
• Insurance coverage
• Generic availability
• Medical history
• Preference for daily versus weekly therapy

Is Compounded Liraglutide Generic Saxenda?

No.

Compounded liraglutide is not an FDA-approved generic.

A compounded preparation does not undergo FDA premarket approval for:

• Safety
• Effectiveness
• Bioequivalence
• Manufacturing consistency
• Potency
• Stability

Patients can review compounded liraglutide for weight loss for a detailed discussion.

When Might Compounded Liraglutide Be Considered?

Compounding may be appropriate only when applicable federal and state requirements are satisfied and the patient's medical needs support use of a compounded preparation.

The existence of compounded liraglutide does not mean:

• It is generic Saxenda
• It has been FDA-approved
• It is clinically proven equivalent to Saxenda
• Every pharmacy may legally produce it in unlimited quantities

Availability and regulatory status should be verified at the time of prescribing.

What Are the Most Common Saxenda Side Effects?

Current safety information lists the following among the most common adverse reactions:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Injection-site reactions
• Headache
• Hypoglycemia
• Indigestion
• Fatigue
• Dizziness
• Abdominal pain
• Increased lipase
• Upper abdominal pain
• Fever
• Gastroenteritis

Patients can review common side effects of GLP-1 medications .

Why Does Saxenda Cause Nausea?

Liraglutide affects appetite pathways and slows gastric emptying.

Nausea is especially common during dose escalation.

Symptoms may be more noticeable when:

• Meals are large
• Meals are very high in fat
• A patient eats beyond comfortable fullness
• Fluid intake is inadequate
• The dose has recently increased

Nausea often improves as the body adapts.

Persistent or severe symptoms require medical review.

Nutrition Strategies for Better Saxenda Tolerance

Depending on symptoms, practical strategies may include:

• Eating smaller meals
• Eating slowly
• Stopping when comfortably full
• Avoiding very large high-fat meals
• Maintaining adequate fluid intake
• Increasing fiber gradually when appropriate
• Prioritizing protein and nutrient-dense foods

Nutritional counseling can help patients maintain adequate nutrition while appetite is reduced.

Saxenda and Constipation

Constipation can occur during treatment.

Possible contributing factors include:

• Reduced food intake
• Reduced fluid intake
• Slower gastrointestinal transit
• Low fiber intake
• Reduced physical activity

Persistent constipation or severe abdominal symptoms should be discussed with a clinician.

Saxenda and Pancreatitis

Acute pancreatitis, including severe forms, has been observed with GLP-1 receptor agonists including liraglutide.

Symptoms can include:

• Persistent severe abdominal pain
• Pain radiating to the back
• Nausea
• Vomiting

Patients with symptoms concerning for pancreatitis require prompt medical evaluation.

Saxenda and Gallbladder Disease

Gallstones and gallbladder inflammation occurred more often with Saxenda than placebo in clinical trials.

Substantial or rapid weight loss can also increase gallstone risk.

Patients should report:

• Persistent right-upper-abdominal pain
• Fever
• Jaundice
• Persistent vomiting

Saxenda and Low Blood Sugar

Hypoglycemia risk is especially important in adults with type 2 diabetes who also use:

• Insulin
• Sulfonylureas
• Other insulin-secretagogue medications

The dose of these medications may need adjustment.

Hypoglycemia has also occurred in pediatric patients without type 2 diabetes.

Saxenda and Increased Heart Rate

Clinical trials found an average increase in resting heart rate of approximately 2 to 3 beats per minute.

Patients should report:

• Persistent palpitations
• Racing heartbeat at rest
• Unexplained sustained heart-rate increase

Current guidance recommends discontinuing Saxenda when a sustained resting-heart-rate increase occurs.

Saxenda and Kidney Injury

Severe gastrointestinal symptoms can cause dehydration.

Volume depletion can contribute to acute kidney injury and, in some cases, dialysis may be required.

Risk is particularly important when patients experience persistent:

• Vomiting
• Diarrhea
• Difficulty drinking enough fluid

Kidney function should be monitored when clinically appropriate.

Saxenda and Severe Gastrointestinal Symptoms

Saxenda can cause severe gastrointestinal adverse reactions.

Current safety information states that Saxenda is not recommended in patients with severe gastroparesis.

Patients should report:

• Persistent vomiting
• Severe prolonged fullness
• Difficulty maintaining nutrition
• Severe abdominal pain

Saxenda and Anesthesia

Liraglutide delays gastric emptying.

Rare postmarketing reports of pulmonary aspiration have occurred in patients using GLP-1 receptor agonists during general anesthesia or deep sedation despite following fasting instructions.

Patients should tell the procedural team they use Saxenda before:

• Surgery
• Endoscopy
• Procedures requiring deep sedation
• Procedures requiring general anesthesia

Thyroid C-Cell Tumor Warning

Saxenda carries an FDA boxed warning related to thyroid C-cell tumors observed in rodents.

It is unknown whether liraglutide causes medullary thyroid carcinoma in humans.

Saxenda is contraindicated in patients with:

• A personal history of medullary thyroid carcinoma
• A family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2

Patients should report:

• A neck mass
• Persistent hoarseness
• Difficulty swallowing
• Unexplained shortness of breath

Serious Allergic Reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with liraglutide.

A patient with a prior serious hypersensitivity reaction to liraglutide or Saxenda excipients should not use the medication.

What Happened to the Saxenda Suicidal-Ideation Warning?

Earlier Saxenda labeling included a warning concerning suicidal behavior and ideation.

In January 2026, FDA announced that a comprehensive review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications.

FDA requested removal of that warning from Saxenda, Wegovy and Zepbound labeling.

The current safety information no longer includes that prior warning.

Patients should still seek appropriate mental-health care for new depression, suicidal thoughts or other concerning mood changes regardless of medication use.

Saxenda and Pregnancy

Intentional weight reduction during pregnancy is generally not an appropriate treatment goal.

Current Saxenda prescribing information states that the medication should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus.

Patients who are pregnant or planning pregnancy should discuss treatment with their clinician rather than continuing a weight-loss medication without reassessment.

Saxenda and Breastfeeding

There are no adequate human data establishing the presence of liraglutide in breast milk.

Liraglutide was present in milk in animal studies.

Breastfeeding decisions should be individualized according to maternal health needs and potential infant risk.

Can Saxenda Be Used With Wegovy?

Routine combined use is not recommended.

Both medications activate GLP-1 receptors.

Current Saxenda information advises against combining liraglutide with another GLP-1 receptor agonist.

Can Saxenda Be Used With Ozempic?

Routine combined use is not recommended.

Ozempic contains semaglutide, another GLP-1 receptor agonist.

Can Saxenda Be Used With Zepbound?

Routine combined use is not recommended.

Zepbound contains tirzepatide, which also activates the GLP-1 receptor.

Can Saxenda Be Used With Mounjaro?

Routine combined use is not recommended.

Mounjaro also contains tirzepatide and has overlapping incretin activity.

Can Saxenda Be Used With Victoza?

No.

Saxenda and Victoza both contain liraglutide.

Using them together would duplicate the same active ingredient.

How Long Does Saxenda Take to Work?

Some patients notice appetite changes during the first few weeks.

Clinically meaningful weight loss develops over months.

The 16-week evaluation is particularly important because it provides an early indication of whether continued treatment is likely to produce sufficient benefit.

How Long Can Saxenda Be Used?

Saxenda was approved for chronic weight management rather than short-term use.

Long-term treatment has been studied for up to three years in selected clinical-trial populations.

Continuation depends on:

• Weight response
• Medical benefit
• Tolerability
• Access
• Patient preference
• Availability of the branded or generic product

Because branded Saxenda is scheduled for discontinuation in 2027, current users should develop a transition plan.

Will Weight Return After Saxenda Is Stopped?

Weight regain can occur after stopping obesity medication.

Appetite-regulation effects diminish when liraglutide is discontinued.

A maintenance plan should address:

• Nutrition
• Physical activity
• Resistance training
• Weight monitoring
• Medication transition when appropriate
• Behavioral support

Body Composition During Saxenda Therapy

The scale measures total weight but does not distinguish fat mass from lean tissue.

Patients losing substantial weight may benefit from body composition analysis .

Measurements can include:

• Body-fat percentage
• Lean mass
• Visceral fat
• Total weight

Body composition tracking can help determine whether the quality of weight loss remains favorable.

Why Preserve Muscle During Weight Loss?

Substantial weight reduction can include some lean-tissue loss.

Lean tissue contributes to:

• Strength
• Mobility
• Metabolic health
• Bone support
• Healthy aging

Older adults and patients with low baseline muscle mass may require additional evaluation for sarcopenia.

How Can Patients Support Muscle Preservation?

Strategies may include:

• Adequate dietary protein
• Resistance training
• Appropriate calorie intake
• Monitoring strength
• Correcting nutrient deficiencies

Personal training for weight loss may help patients build a structured exercise program.

Nutrition During Saxenda Therapy

Reduced appetite can make calorie reduction easier, but it can also make it harder to consume enough protein, fiber and micronutrients.

A balanced plan should provide adequate:

• Protein
• Fiber
• Fluids
• Vitamins
• Minerals

Extreme calorie restriction is not the goal.

Saxenda and Metabolic Health

Weight reduction can improve several markers associated with metabolic syndrome .

Depending on the patient, monitoring may include:

• Fasting glucose
• Hemoglobin A1c
• Blood pressure
• Waist circumference
• Lipid profile

What Happens at a Saxenda Consultation?

A physician-guided evaluation may include:

• Current weight and BMI
• Waist circumference
• Weight history
• Previous weight-loss treatments
• Current medications
• Blood pressure
• Glucose and hemoglobin A1c
• Lipid profile
• Kidney function
• Liver function
• Pancreatitis history
• Gallbladder history
• Gastrointestinal symptoms
• Sleep apnea
• Pregnancy plans
• Nutrition and activity habits
• Current or anticipated Saxenda availability

A consultation does not guarantee that Saxenda or generic liraglutide will be prescribed.

Laboratory Testing During Liraglutide Therapy

Testing depends on the patient's medical history.

Possible measurements include:

• Fasting glucose
• Hemoglobin A1c
• Kidney function
• Liver function
• Lipid profile
• Additional blood testing when clinically appropriate

How Is Progress Monitored?

Useful monitoring can include:

• Body weight
• Percentage weight change
• Waist circumference
• Body-fat percentage
• Lean mass
• Blood pressure
• Appetite
• Gastrointestinal symptoms
• Resting heart rate
• Physical strength
• Glucose and A1c when relevant
• Medication adherence

Monitoring can identify a weight-loss plateau , inadequate early response or side effects that require a treatment change.

What If Saxenda Is Not Working Well Enough?

For adults, the first major question is whether at least 4% of baseline body weight has been lost by week 16.

If not, current guidance recommends discontinuing Saxenda.

If the patient initially responds but later reaches a plateau, a physician may review:

• Medication adherence
• Calorie intake
• Protein intake
• Physical activity
• Sleep
• Other medications associated with weight gain
• Metabolic conditions
• Body composition

What If Saxenda Is Not Tolerated?

A physician may consider:

• Delaying dose escalation
• Reviewing meal size and meal composition
• Improving hydration
• Treating specific gastrointestinal symptoms when appropriate
• Switching to another FDA-approved obesity medication

Patients can review Saxenda alternatives .

What Are the Main Alternatives to Saxenda?

Potential FDA-approved alternatives include:

• Wegovy
• Zepbound
• FDA-approved generic liraglutide referencing Saxenda
• Qsymia
• Contrave
• Orlistat
• Short-term phentermine in selected adults

The best alternative depends on effectiveness, tolerability, medical history, cost and treatment goals.

Frequently Asked Questions About Liraglutide Injections and Saxenda Therapy

What is Saxenda?

Saxenda is an FDA-approved once-daily liraglutide injection for chronic weight management in qualifying adults and adolescents age 12 years and older who weigh more than 60 kg.

Is Saxenda liraglutide?

Yes. Liraglutide is the active ingredient in Saxenda.

Is liraglutide a GLP-1 medication?

Yes. Liraglutide is a GLP-1 receptor agonist.

Is liraglutide a peptide?

Yes. Liraglutide is a modified peptide analogue of human GLP-1.

How often is Saxenda injected?

Once daily.

What is the starting Saxenda dose?

The FDA-approved starting dose is 0.6 mg once daily for the first week.

What is the full Saxenda dose?

The recommended adult maintenance dose is 3.0 mg once daily.

How quickly is Saxenda increased?

The dose generally increases by 0.6 mg each week until 3.0 mg daily is reached.

Can I stay on 1.8 mg Saxenda for weight loss?

For adults, the recommended Saxenda maintenance dose is 3.0 mg daily. Lower doses are primarily used for escalation, and patients unable to tolerate 3 mg should be reassessed.

Can adolescents use 2.4 mg?

Current patient guidance notes that an adolescent may be reduced to 2.4 mg daily if 3.0 mg is not tolerated, under clinician direction.

How much weight can you lose with Saxenda?

In the pivotal 56-week SCALE trial, adults receiving liraglutide 3.0 mg lost an average of 8.4 kg compared with 2.8 kg with placebo.

What percentage of patients lose at least 5%?

In the pivotal trial, 63.2% of liraglutide-treated participants lost at least 5% of starting body weight.

What percentage lose more than 10%?

In the same trial, 33.1% of liraglutide-treated participants lost more than 10%.

What is the Saxenda 16-week rule?

Adults should be evaluated 16 weeks after starting treatment. If at least 4% of baseline body weight has not been lost, current guidance recommends discontinuing Saxenda.

Why is 4% weight loss important?

Clinical analyses found that losing at least 4% by week 16 helped identify patients more likely to achieve meaningful one-year weight loss.

Where do I inject Saxenda?

Approved subcutaneous injection sites include the abdomen, thigh and upper arm.

Can Saxenda be taken with food?

Yes. It can be injected at any time of day, independent of meals.

What if I miss a Saxenda dose?

Take the next scheduled daily dose as usual and do not double the dose. If treatment has been missed for three days or more, contact the prescribing clinician about restarting.

Is Saxenda being discontinued?

Yes. Novo Nordisk has announced that branded Saxenda will be discontinued, with final shipments to wholesalers expected in late January 2027.

Why is Saxenda being discontinued?

The manufacturer states that the decision reflects changes in the obesity-treatment market and declining Saxenda use. It is not a safety or quality-related discontinuation.

What happens after Saxenda is discontinued?

Patients can discuss FDA-approved generic liraglutide and other obesity medications with their clinician before branded Saxenda supplies become limited.

Is there a generic Saxenda?

FDA approved the first generic liraglutide injection referencing Saxenda in August 2025.

Is generic liraglutide FDA-approved?

Yes, the approved generic referencing Saxenda completed the FDA generic-drug approval process.

Is compounded liraglutide generic Saxenda?

No. Compounded liraglutide is not FDA-approved and is not an FDA-approved generic.

Is Saxenda better than Wegovy?

Both are FDA-approved obesity medications, but direct STEP 8 evidence found greater average weight reduction with weekly semaglutide 2.4 mg than daily liraglutide 3.0 mg.

Is Saxenda better than Zepbound?

Major tirzepatide obesity trials have reported greater average weight loss than the pivotal liraglutide trials, but there is no major direct Zepbound-versus-Saxenda trial establishing the comparison in the same study population.

Is Saxenda the same as Ozempic?

No. Saxenda contains liraglutide. Ozempic contains semaglutide.

Is Saxenda the same as Mounjaro?

No. Saxenda contains liraglutide. Mounjaro contains tirzepatide.

Is Saxenda the same as Victoza?

No. Both contain liraglutide, but Saxenda is the weight-management brand and Victoza is the diabetes brand with different approved indications and doses.

Can Saxenda and Victoza be used together?

No. They contain the same active ingredient.

Can Saxenda and Wegovy be used together?

Routine combined use is not recommended because both are GLP-1 receptor agonists.

Can Saxenda and Zepbound be used together?

Routine combined use is not recommended because tirzepatide also activates the GLP-1 receptor.

What are the most common Saxenda side effects?

Nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, indigestion, fatigue, dizziness and abdominal discomfort are among the common adverse effects.

Does Saxenda cause nausea?

Yes. Nausea is particularly common when treatment begins or the dose is increased.

Does Saxenda cause constipation?

Yes. Constipation is a recognized adverse effect.

Can Saxenda cause pancreatitis?

Acute pancreatitis has been observed with liraglutide and other GLP-1 receptor agonists. Severe persistent abdominal pain requires prompt medical evaluation.

Can Saxenda cause gallstones?

Yes. Gallstones and gallbladder inflammation occurred more often with Saxenda than placebo in clinical trials.

Can Saxenda affect the kidneys?

Severe vomiting or diarrhea can cause dehydration and acute kidney injury. Patients who cannot maintain fluid intake should contact their clinician.

Can Saxenda cause gastroparesis?

Liraglutide delays gastric emptying and can cause significant gastrointestinal symptoms. Saxenda is not recommended in severe gastroparesis.

Does Saxenda increase heart rate?

Yes. Average resting heart rate increased by approximately 2 to 3 beats per minute in clinical trials. Persistent increases should be evaluated.

Does Saxenda have a thyroid cancer warning?

Yes. Saxenda carries an FDA boxed warning related to thyroid C-cell tumors observed in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Does Saxenda increase suicide risk?

FDA's comprehensive review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of the prior warning from Saxenda labeling in January 2026.

Can Saxenda be used during pregnancy?

Weight-loss treatment should be reassessed during pregnancy. Current prescribing information states that Saxenda should be used during pregnancy only when the potential benefit justifies the potential fetal risk.

Can Saxenda be used while breastfeeding?

Human milk data are limited. The decision should be individualized with the prescribing clinician.

Does Saxenda help prediabetes?

Three-year SCALE research found less progression to type 2 diabetes during liraglutide treatment in adults with obesity and prediabetes. Saxenda is not FDA-approved specifically for diabetes prevention.

Does Saxenda help sleep apnea?

A randomized trial found greater improvement in apnea-hypopnea index and body weight with liraglutide than placebo in adults with obesity and moderate-to-severe sleep apnea. Saxenda does not have a specific FDA OSA indication.

Can teenagers use Saxenda?

Yes. Saxenda is FDA-approved for qualifying adolescents age 12 years and older with obesity and body weight above 60 kg.

Can children under 12 use Saxenda?

The current FDA-approved Saxenda indication does not include children younger than 12.

Does Saxenda cause muscle loss?

Some lean tissue can be lost during substantial weight reduction. Adequate protein, resistance exercise and body-composition monitoring can help support muscle preservation.

Can I exercise while taking Saxenda?

Yes. Increased physical activity is part of the approved treatment approach and can support fitness, insulin sensitivity, muscle preservation and weight maintenance.

How much protein should I eat on Saxenda?

Protein needs vary according to age, body size, kidney function, activity level and rate of weight loss. A clinician or dietitian can help determine an individualized target.

How long can I stay on Saxenda?

Saxenda was designed for chronic weight management when effective and tolerated. Because the branded product is scheduled for discontinuation in 2027, current users should discuss future treatment continuity.

Will I regain weight after stopping Saxenda?

Weight regain can occur when appetite-regulating medication is discontinued. A transition and maintenance plan can help reduce the risk of uncontrolled regain.

What if Saxenda stops working?

A clinician should review the 16-week response, current adherence, nutrition, activity, sleep, medications and body composition before deciding whether treatment should change.

What if I cannot tolerate Saxenda?

A slower titration or another FDA-approved obesity medication may be appropriate depending on the symptoms and medical history.

What are the main Saxenda alternatives?

Alternatives include Wegovy, Zepbound, FDA-approved generic liraglutide, Qsymia, Contrave, orlistat and selected other weight-management approaches.

Can retatrutide replace Saxenda?

Not currently. Retatrutide remains investigational and cannot currently be used in compounding under federal law.

Can I buy liraglutide without a prescription?

Liraglutide is a prescription medication and should be obtained through legitimate prescribing and pharmacy channels.

Should I inject research-grade liraglutide?

No. Products labeled only for laboratory or research use are not intended as medications for human treatment.

Explore Liraglutide Injections and Saxenda Therapy in Fishers, IN

Saxenda remains an established FDA-approved GLP-1 treatment with a large clinical evidence base in chronic weight management.

Its benefits include clinically meaningful weight reduction, support for long-term maintenance and favorable metabolic changes in selected patients.

However, the treatment landscape has changed substantially.

FDA-approved generic liraglutide is now available, newer weekly obesity medications provide additional options, and branded Saxenda is scheduled to be discontinued after final wholesaler shipments in late January 2027.

Patients currently using Saxenda should plan ahead rather than waiting until access becomes limited.

A physician-guided evaluation can help determine whether generic liraglutide, Wegovy, Zepbound or another weight-management strategy is the best next step.

Call (765) 259-0545 or contact Charles Turner MD online to request your consultation.

Medical References

• A Randomized Controlled Trial of Liraglutide 3.0 mg for Weight Management: SCALE Obesity and Prediabetes
• Three Years of Liraglutide for Weight Management and Type 2 Diabetes Risk Reduction in Adults With Prediabetes
• Liraglutide Supports Weight Maintenance and Additional Weight Reduction After Diet-Induced Weight Loss: SCALE Maintenance
• Liraglutide 3.0 mg Produces Significant Weight Reduction in Adults With Type 2 Diabetes: SCALE Diabetes
• Liraglutide Reduces Weight and Obstructive Sleep Apnea Severity in Adults With Obesity: SCALE Sleep Apnea
• Liraglutide Improves BMI Outcomes in Adolescents With Obesity
• Liraglutide Plus Intensive Behavioral Therapy Produces Greater Weight Reduction Than Behavioral Therapy Alone: SCALE IBT
• Intensive Behavioral Therapy Combined With Liraglutide Produces Clinically Meaningful Weight Reduction
• Early Weight Loss With Liraglutide Predicts Greater One-Year Weight Reduction and Improved Clinical Markers